Updates are available Correction dated 2020-02-12
Click to view Correction: https://doi.org/10.1186/s13063-020-4107-8
-
Authors
Tegtmeier, Frank
,
Schinzel, Reinhard http://orcid.org/0000-0001-7299-7063
Beer, Ronny
Bulters, Diederik
LeFrant, Jean-Yves
Sahuquillo, Joan
Unterberg, Andreas
Andrews, Peter
Belli, Antonio
Ibanez, Javier
Lagares, Alfonso
Mokry, Michael
Willschke, Harald
Flüh, Charlotte
Schmutzhard, Erich
-
Funding
Funding for this research was provided by:
vasopharm GmbH (n.a.)
- License Information
-
More Information
Article History
Received: 18 October 2019
Accepted: 5 December 2019
First Online: 14 January 2020
Change Date: 12 February 2020
Change Type: Correction
Change Details: After publication of our article [1] the authors have notified us that one of the names has been incorrectly spelled.
Ethics approval and consent to participate
: This trial is conducted in patients who are unable to consent, therefore the patient’s legal representative provides consent for the patient according to local regulations (next-of-kin, appointed representative). All patients who have recovered sufficiently will additionally be asked to re-consent.Approval for this protocol has been obtained from the leading ethic committee “Ethikkommission der Medizinischen Universität Innsbruck, Austria” (date of approval 31 May 2016; no. AN2016–0035 359/2.1). Subsequent approval by local and central ethics committees has been obtained according to local regulations (see InternalRef removed).The competent regulatory authorities of all countries have approved the trial.
: As clinical images or other clinical and personal data are not shown, consent for publication is not applicable.
: FT and RS are full-time employees of vasopharm GmbH. The other authors declare that they have no competing interests.
